BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Urbini M, Indio V, Astolfi A, Tarantino G, Renne SL, Pilotti S, Dei Tos AP, Maestro R, Collini P, Nannini M, Saponara M, Murrone L, Dagrada GP, Colombo C, Gronchi A, Pession A, Casali PG, Stacchiotti S, Pantaleo MA. Identification of an Actionable Mutation of KIT in a Case of Extraskeletal Myxoid Chondrosarcoma. Int J Mol Sci 2018;19:E1855. [PMID: 29937513 DOI: 10.3390/ijms19071855] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Jennings B, Rieth J, Snyders T, Milhem M. Sustained response to imatinib in patient with extraskeletal myxoid chondrosarcoma and novel KIT mutation. BMJ Case Rep 2021;14:e242039. [PMID: 34446510 DOI: 10.1136/bcr-2021-242039] [Reference Citation Analysis]
2 Wang C, You ZJ, Chen XY, Lin J, Wu YJ. Mutation of KIT in cellular extraskeletal myxoid chondrosarcoma: a case report and literature review. Diagn Pathol 2022;17:42. [PMID: 35488288 DOI: 10.1186/s13000-022-01222-7] [Reference Citation Analysis]
3 Clanchy FIL. Rationale for Early Detection of EWSR1 Translocation-Associated Sarcoma Biomarkers in Liquid Biopsy. Cancers (Basel) 2021;13:824. [PMID: 33669307 DOI: 10.3390/cancers13040824] [Reference Citation Analysis]